Medication for Parkinson Disease

Drug treatment of Parkinson disease is symptomatic. The main agents are levodopa (the most effective single agent for motor symptom control and the cornerstone of treatment), dopamine agonists, monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergic agents (now used only in limited, specific circumstances).

Advanced device assisted therapies (deep brain stimulation and continuous infusion therapies) are reserved for more advanced disease. Selection and sequencing are individualised according to patient age, symptom severity, clinical profile and disease stage.

The central challenge is balancing effective, sustained symptom control against the cumulative risk of long term motor complications (particularly dyskinesia and motor fluctuations) from prolonged levodopa exposure. This risk has historically influenced treatment sequencing, particularly in younger patients.

General treatment principles

• Levodopa is invariably combined with a peripheral decarboxylase inhibitor (carbidopa or benserazide). This reduces peripheral conversion to dopamine and the associated adverse effects (particularly nausea) while allowing adequate central nervous system penetration. It is the most effective single agent for the core motor symptoms.
• Long term levodopa use is associated with motor fluctuations: "wearing off" of symptom control before the next scheduled dose and, in more advanced disease, unpredictable "on-off" fluctuations. It is also associated with dyskinesia (involuntary, often choreiform movements at peak dose or during the transition between "on" and "off" states).
• The risk of these complications increases with cumulative treatment duration and, to some extent, with the dosing pattern and total daily dose.
• Younger patients (generally under approximately sixty to seventy years, according to varying guidelines) are frequently, though not universally, started on a dopamine agonist or monoamine oxidase B inhibitor rather than levodopa. The aim is to delay levodopa initiation and so reduce cumulative lifetime exposure and motor complication risk, given the longer anticipated disease duration.
• The benefit of this approach compared with earlier levodopa initiation remains debated. Some contemporary evidence suggests that delaying levodopa reduces long term motor complication risk less than previously believed.
• Older patients, or those with significant functional impairment from motor symptoms at presentation, are generally started on levodopa. It has superior symptomatic efficacy and a more favourable tolerability profile than dopamine agonists, which carry adverse effects of particular concern in older patients.

• The clinical features relevant to this entry are the adverse effects of the medication classes rather than a distinct disease presentation. Careful patient education about these effects is an essential part of safe, informed prescribing.
• Dopamine agonists carry an important risk of impulse control disorders (including pathological gambling, hypersexuality, compulsive shopping, and binge eating). These can be seriously, sometimes profoundly, life disrupting.
• Impulse control disorders can develop insidiously. Patients often have limited insight into the medication induced nature of the behaviour and may not disclose it, so ask direct questions at regular intervals throughout treatment.
• Other adverse effects of dopamine agonists include significant sedation, with a risk of sudden, unpredictable "sleep attacks" that matters for driving safety, and, less commonly, hallucinations, particularly in older patients.
• Levodopa related motor complications, comprising "wearing off" and dyskinesia, are the principal clinically significant adverse effects of levodopa. Some patients also develop neuropsychiatric effects including hallucinations and confusion, which are more common in older patients or those with significant coexisting cognitive impairment.
• Monoamine oxidase B inhibitors are generally well tolerated, with a more favourable adverse effect profile than the other classes. Watch for drug interactions: certain other serotonergic medications (a theoretical, though in practice uncommon, risk of serotonin syndrome with combination use) and certain sympathomimetic agents.

• This entry addresses medication management rather than a specific diagnostic process. Regular, structured assessment of treatment response is an integral part of management across the full course of treatment. This includes specific assessment for motor fluctuations and dyskinesia.
• Monitor for adverse effects, including direct, regular enquiry about impulse control symptoms in any patient treated with a dopamine agonist.
• Assess the pattern and timing of any motor fluctuations, ideally with a structured patient diary recording medication dose times relative to the onset and offset of adequate symptom control. This supports rational, individualised treatment adjustment as the disease progresses and treatment requirements evolve.

• Levodopa, given orally with carbidopa or benserazide, is typically started at a low dose and titrated gradually according to clinical response. Dosing frequency and total daily dose are adjusted over time as the disease progresses.
• Levodopa is ideally taken on an empty stomach or with minimal protein, because it competes with dietary amino acids for intestinal absorption and blood brain barrier transport. This matters particularly for patients with inconsistent or delayed medication response.
• Dopamine agonists include pramipexole, ropinirole, and rotigotine (available as a transdermal patch offering more continuous drug delivery). They are used as initial monotherapy in appropriately selected younger patients or as an adjunct to levodopa in more established disease.
• Educate patients and families about the risk of impulse control disorders and excessive daytime sedation. Screen for these regularly and proactively throughout treatment, and reduce the dose or stop promptly if they develop.
• Monoamine oxidase B inhibitors (selegiline or rasagiline) give modest symptomatic benefit as monotherapy in early disease. In more established disease they are used as an adjunct to levodopa to smooth out motor fluctuations. They are generally well tolerated across the disease spectrum.
• Catechol-O-methyltransferase inhibitors (entacapone or opicapone) are used as an adjunct to levodopa. They reduce peripheral levodopa metabolism and so extend its effective duration of action.
• These inhibitors are particularly useful for "wearing off" in patients with established motor fluctuations. Entacapone has a short duration of action and is given with each levodopa dose. Opicapone is given as a single, separate daily dose.
• Amantadine gives modest symptomatic benefit for motor symptoms and has a useful, targeted role in established levodopa induced dyskinesia.
• Advanced device assisted therapies are deep brain stimulation (typically targeting the subthalamic nucleus or globus pallidus internus) and continuous infusion therapies. Infusion options are levodopa-carbidopa intestinal gel delivered via a surgically placed jejunal tube, or continuous subcutaneous apomorphine infusion (a potent dopamine agonist with specific administration considerations).
• Consider these therapies in selected patients with advanced disease who have significant, troublesome motor fluctuations or dyskinesia not controlled by optimised oral medication.
• Careful, structured multidisciplinary selection is essential to optimise outcomes with these more invasive, resource intensive treatments. It includes assessment of cognitive status, as outcomes with deep brain stimulation are generally less favourable in patients with significant coexisting cognitive impairment.
• Anticholinergic medication, historically used more widely, now has a very limited role. It is generally reserved for younger patients with prominent, troublesome tremor not responding to other approaches.
• Its adverse effect profile generally outweighs its modest symptomatic benefit in the great majority of patients. Adverse effects include cognitive impairment, particularly problematic in older patients, and the standard peripheral anticholinergic effects.
• Review and adjust medication regularly, assessing both motor symptom control and the full range of medication related adverse effects. Close coordination between the patient, their family, and the specialist neurology team throughout the prolonged, progressive disease course underpins safe, effective, individualised management.